Funding round brings in $33M for cholesterol drug developer

04/26/2013 | Xconomy

Esperion Therapeutics said it secured $33 million in a preferred stock funding round led by Longitude Capital and it will use the money to fund clinical trials. The Ann Arbor, Mich.-based firm is developing a cholesterol-lowering drug for patients who can't take statins. The drug, called ETC-1002, is in midstage development.

View Full Article in:

Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN